Investors / France / Lauxera Capital Partners
Lauxera Capital Partners
Venture capital · Paris, France · Europe
Lauxera Capital Partners is an independent, international investment fund focused on growth companies in Healthtech. It invests in businesses that have generated significant revenue and reached breakeven or early profitability, and supports them with management experience, business development and talent support.
Invests inHealthcare & Biotech
In its own wordshealthtechmedical devicesdigital healthdiagnosticslife science toolspharma services
Your fit with Lauxera Capital Partners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsLauxera Capital Partners lists 13 checked portfolio companies on its own site and is named in 2 funding rounds, 1 of them as lead. Its most frequent entry is Growth, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (93%) and Cybersecurity (7%). It invests most often alongside Amadeus Capital Partners, BGF and Headline.
Counts come from funding rounds that name Lauxera Capital Partners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Lauxera Capital Partners' whole history. Rounds on record name 2 companies; its own site lists 13. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 0% |
| Growth | 100% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 2 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 33th | 13 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 87th | 15% of companies confirmed by a round |
| Sector focus | 96th | 93% in its largest sector |
| Reach | 88th | 7 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Amadeus Capital Partners | 1 |
| BGF | 1 |
| Headline | 1 |
| Heartcore | 1 |
| Intuitive Ventures | 1 |
| Longwall Ventures | 1 |
| Oxford Investment Consultants | 1 |
| Perivoli Innovations Venture Investment Trust | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers13100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 93% | 15% |
| Cybersecurity | 7% | 4% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Amadeus Capital Partners
Compare Lauxera Capital Partners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Lauxera Capital Partners| Date | Company | Stage |
|---|---|---|
| 12 Aug 2026 | Series C+ | |
| 30 Jul 2026 | Series C+ Led |
Round details for Lauxera Capital Partners
Amounts, full round histories and every co-investor in Lauxera Capital Partners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
13 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Acandis develops and provides medical technology solutions for the treatment of hemorrhagic and ischemic strokes. | Healthcare & Biotech | Portfolio page | ||
| The company provides imaging solutions and delivers imaging trials for drug development | Healthcare & Biotech | Portfolio page | ||
| BioLamina provides products for cell culture, including full-length human recombinant laminins for 2D and 3D applications. | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides organ preservation and perfusion solutions for organ transplantation. | Healthcare & Biotech | Aug 2026Series C+ | Page + round | |
| GenePlanet does preventive genetic testing | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| Lumicks develops and provides technologies for understanding molecular interactions and cell binding, particularly for immunotherapy and molecular biology research. | Healthcare & Biotech | Portfolio page | ||
| Matrix One provides software solutions for life science companies | Healthcare & Biotech | Portfolio page | ||
| Natural Cycles provides a birth control app that helps users track their fertility and menstrual cycle | Healthcare & Biotech | Portfolio page | ||
| OrganOx develops technologies to enhance organ transplantation, including normothermic machine perfusion | Healthcare & Biotech | Portfolio page | ||
| Ospi provides artificial intelligence and data solutions for healthcare services | Healthcare & Biotech | Portfolio page | ||
| Reapplix develops and provides a personalized wound healing treatment using a patient's own blood to create a patch that accelerates wound healing | Healthcare & Biotech | Portfolio page | ||
| Synovo Group edits software and provides IT solutions for healthcare transportation and related services. | Healthcare & BiotechCybersecurity | Portfolio page | ||
| Veranex provides services including design and development, clinical research, and regulatory consulting for device and IVD companies. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- lauxera.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 30 Jul 2026
- Companies checked
- 13
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Lauxera Capital Partners' profile as data
Pull Lauxera Capital Partners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/lauxera.com
# also
GET /v1/firms/lauxera.com/portfolio
GET /v1/firms/lauxera.com/coinvestors
GET /v1/firms/lauxera.com/news